Management of Drug Resistance in Mantle Cell Lymphoma - Archive ouverte HAL Access content directly
Journal Articles Cancers Year : 2020

Management of Drug Resistance in Mantle Cell Lymphoma

(1) , (2)
1
2

Abstract

Mantle cell lymphoma (MCL) is a rare but aggressive B-cell hemopathy characterized by the translocation t(11;14)(q13;q32) that leads to the overexpression of the cell cycle regulatory protein cyclin D1. This translocation is the initial event of the lymphomagenesis, but tumor cells can acquire additional alterations allowing the progression of the disease with a more aggressive phenotype and a tight dependency on microenvironment signaling. To date, the chemotherapeutic-based standard care is largely inefficient and despite the recent advent of different targeted therapies including proteasome inhibitors, immunomodulatory drugs, tyrosine kinase inhibitors, relapses are frequent and are generally related to a dismal prognosis. As a result, MCL remains an incurable disease. In this review, we will present the molecular mechanisms of drug resistance learned from both preclinical and clinical experiences in MCL, detailing the main tumor intrinsic processes and signaling pathways associated to therapeutic drug escape. We will also discuss the possibility to counteract the acquisition of drug refractoriness through the design of more efficient strategies, with an emphasis on the most recent combination approaches.
Fichier principal
Vignette du fichier
Roué Cancers 2020.pdf (1.18 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

hal-02866782 , version 1 (12-06-2020)

Identifiers

Cite

Gaël Roué, Brigitte Sola. Management of Drug Resistance in Mantle Cell Lymphoma. Cancers, 2020, 12, ⟨10.3390/cancers12061565⟩. ⟨hal-02866782⟩
47 View
42 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More